The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependence.
Abstract
PURPOSE: To evaluate the efficacy and feasibility of high-dose ifosfamide (HDI) at a total dose of 14 g/m2 per cycle with mesna in combination with granulocyte colony-stimulating factor (G-CSF) in adult patients with sarcomas. PATIENTS AND METHODS: Between July 1991 and February 1994, 74 patients with sarcomas (37 bone and 37 soft tissue) were treated on two simultaneous phase II studies that evaluated HDI given as a continuous infusion over 74 hours. G-CSF was started on day 5 at 5 microg/kg/d until recovery of granulocyte count. Additionally, between March 1993 and March 1994, 15 similar patients with previously treated bone or soft tissue sarcomas were treated on a pilot study in which the same total dose of ifosfamide was administered by a bolus schedule, along with mesna and G-CSF. Patients were treated until maximal response, and where possible, surgical resection of gross disease was performed. RESULTS: Seventy-two patients from the phase II study using continuous infusion are assessable for response. Four complete responses (CRs) and 17 partial responses (PRs) were noted, for an overall response rate of 29% (95% confidence interval [CI], 19% to 39%). The response rate was 40% (95% CI, 24% to 56%) for bone sarcomas and 19% (95% CI, 6% to 32%) for soft tissue sarcomas. Fourteen patients from the pilot study that used a bolus schedule are assessable for response. One CR and seven PRs were noted, for an overall response rate of 57% (95% CI, 31% to 83%) and a response rate of 45% for soft tissue sarcomas. Two patients developed grade 3 to 4 renal toxicity, three developed grade 3 CNS toxicity, one had possible grade 3 cardiac toxicity, and two developed severe painful peripheral neuropathy. There were no treatment-related deaths. CONCLUSION: HDI at 14 g/m2 with mesna and G-CSF is an active salvage regimen for patients with bone and soft tissue sarcomas. There is a definite positive dose-response curve, and bolus administration appears to be more active than continuous infusion.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Optimal two-stage designs for phase II clinical trials.
Simon, R. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90015-9 · Cited by 3,636
Edmonson, J. H., Ryan, L. M., Blum, R. H., Brooks, J. S., Shiraki, M., Frytak, S., & Parkinson, D. R. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.7.1269 · Cited by 516
Antman, K. H., Crowley, J. J., Balcerzak, S. P., Rivkin, S. E., Weiss, G. R., ELIAS, A. D., Natale, R. B., Cooper, R. M., Barlogie, B., & Trump, D. L. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.7.1276 · Cited by 478
Bramwell, V. H. C., Mouridsen, H. T., Santoro, A., Blackledge, G., Somers, R., Verwey, J., Dombernowsky, P., Onsrud, M., Thomas, D., Sylvester, R., et al. (1987) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(87)90075-7 · Cited by 243
Antman, K. H., Ryan, L., Elias, A., Sherman, D., & Grier, H. E. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.1.126 · Cited by 241
Le Cesne, A., Antoine, E., Spielmann, M., Le Chevalier, T., Brain, E., Toussaint, C., Janin, N., Kayitalire, L., Fontaine, F., & Genin, J. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.7.1600 · Cited by 207
High-dose ifosfamide with mesna uroprotection: a phase I study.
ELIAS, A. D., Eder, J. P., Shea, T., Begg, C. B., Frei, E., & Antman, K. H. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.1.170 · Cited by 146
Single-agent ifosfamide studies in sarcomas of soft tissue and bone: the M.D. Anderson experience.
Benjamin, R. S., Legha, S. S., PATEL, S. R., et al. (1993) · PubMed · Cited by 85
Self-citation
Cited by
Cormier, J. N., & Pollock, R. E. (2004) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.54.2.94 · Cited by 835
Singer, S., Antonescu, C. R., Riedel, E., & Brennan, M. F. (2003) · Annals of Surgery · doi:10.1097/01.sla.0000086542.11899.38 · Cited by 670
Chemotherapy‐induced neuropathy
Windebank, A. J., & Grisold, W. (2008) · Journal of the Peripheral Nervous System · doi:10.1111/j.1529-8027.2008.00156.x · Cited by 613
Verstappen, C. C. P., Heimans, J. J., Hoekman, K., & Postma, T. J. (2003) · Drugs · doi:10.2165/00003495-200363150-00003 · Cited by 456
Ferrari, S., Smeland, S., Mercuri, M., Bertoni, F., Longhi, A., Ruggieri, P., Alvegard, T. A., Picci, P., Capanna, R., Bernini, G., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2004.00.5785 · Cited by 435
Metadata
- Authors
- Patel, S. R., Vadhan-Raj, S., Papadopolous, N., Plager, C., Burgess, M. A., Hays, C., & Benjamin, R. S.
- Venue
- Journal of Clinical Oncology
- Published
- 1997-06
- Volume
- 15
- Issue
- 6
- Pages
- 2378-2384
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1798881598
- Cited by
- 257
- References
- 8
- FWCI
- 7.73
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependence. https://app.cochat.ai/papers/10.1200/jco.1997.15.6.2378
- The paper
- Patel, S. R., Vadhan-Raj, S., Papadopolous, N., Plager, C., Burgess, M. A., Hays, C., & Benjamin, R. S. (1997). High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependence. Journal of Clinical Oncology. https://doi.org/10.1200/jco.1997.15.6.2378
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.